FRITZ ABERGER,WOLFGANG GRUBER,JOHANN LEBAN,HELLA KOHLHOF,DANIEL VITT,ROLAND BAUMGARTNER
申请号：
GB201410735
公开号：
GB2519623A
申请日:
2014.06.17
申请国别(地区):
GB
年份:
2015
代理人:
摘要：
DYRK1B inhibition for the treatment of cancer (I) A Dual-Specificity-Tyrosine-Regulated-Kinase 1B (DYRK1B or Minibrain-Regulated-Kinase MIRK) inhibitor for use in the treatment of cancer wherein in the cancer and/or in cells of the cancer the hedgehog signalling pathway is activated. Preferably the DYRK1B inhibitor is a compound of formula (I) (N-2-pyrimidinyl-6-(trifluoromethyl)-1H-benzimidazol-2-amine). Preferably in the cancer and/or in cells of the cancer the activation of the hedgehog signalling pathway is independent of signalling by the G-protein-coupled receptor Smoothened.
